New York, December 07, 2016-- Moody's Investors Service said that a recent announcement by Abbott Laboratories does not change its expectations for the company's future ratings. On December 7th, Abbott ...
- American City Business Journals•yesterday
Abbott Laboratories on Wednesday fired the latest salvo in its legal battle with Alere over their $5.8 billion buyout agreement, suing the troubled Waltham diagnostics firm in an effort to terminate the deal. Chicago-based Abbott (ABT) filed a complaint in the Delaware Court of Chancery, where large corporations often go to hash out business disputes, asking a judge to terminate its February buyout on the grounds that Alere (ALR) has been severely damaged since then and has stonewalled requests for information. Alere previously sued Abbott in the same Delaware court in August to enforce the deal.
"We know that the time to be greedy is when others are fearful and fearful when others are greedy, so we do not mind seeing AAII Bullish levels diminish nor are we unhappy to see the exodus from bonds slow somewhat.."
ABT : Summary for Abbott Laboratories Common Stoc - Yahoo Finance
Abbott Laboratories (ABT)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||38.66 x 11900|
|Ask||38.67 x 3400|
|Day's Range||38.01 - 38.79|
|52 Week Range||36.00 - 46.22|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||42.23|
|Dividend & Yield||1.04 (2.71%)|
|1y Target Est||N/A|